TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10522283
Drug: Sequential group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential group (S)
Study: 8770718
Drug: Adequate antidepressant
Normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate antidepressant treatment (dosage not specified)
Study: 8770718
Drug: Low-intensity antidepressant
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity antidepressant treatment (dosage not specified)
Study: 8770718
Drug: Low-intensity treatment
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity treatment
Study: 8770718
Drug: Higher-intensity treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-intensity treatment
Study: 7006619
Drug: Propranolol, given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, given four times daily
Study: 7006619
Drug: Penbutolol, given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol, given once daily
Study: 29860661
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg vitamin C daily 2 days after RAIT
Study: 29860661
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg vitamin C daily 2 days before to 2 days after RAIT
Study: 29860661
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg vitamin C daily 2 days before RAIT
Study: 17192497
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg intranasal ketorolac
Study: 17192497
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg intranasal ketorolac
Study: 17192497
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg intramuscular ketorolac
Study: 8988064
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg intramuscular ketorolac
Study: 17192497
Drug: Intranasal ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketorolac (both doses)
Study: 15292384
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (MeCCNU, vincristine, 5-fluorouracil)
Study: 15292384
Drug: Adjuvant immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant immunotherapy (bacillus Calmette‐Guérin)
Study: 11800507
Drug: Zolpidem 10
Normalized name: zolpidem 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 10 mg 5 nights/week
Study: 10526810
Drug: Propofol (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1, 2, 3, 4, 5, or 6 micrograms/ml) and Sufentanil (0.1, 0.2, 0.3, 0.5, or 1.0 ng/ml) target blood concentrations
Study: 2264951
Drug: Baclofen 40
Normalized name: baclofen 40,000 MCG per 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen 40 mg/day
Study: 2264951
Drug: Baclofen 80
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baclofen 80 mg/day
Study: 375802
Drug: Cefazolin, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin, 1 gm intramuscularly preoperatively, then 0.5 gm every six hours for four doses
Study: 21385856
Drug: oral 6‐mercaptopurine
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral 6‐mercaptopurine and intramuscular methotrexate (arm 1)
Study: 21385856
Drug: no further
Approvals — FDA: no, EMA: no, PMDA: no
Description: no further therapy (arm 4)
Study: 16472976
Drug: Branched-chain-enriched amino
Normalized name: Machilus thunbergii branch extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched-chain-enriched amino acid mixture infused at 82 mg x h(‐1) x kg(‐1) for 3 hours
Study: 16472976
Drug: Balanced amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced amino acid infusion
Study: 10809242
Drug: 2.0 L
Normalized name: NUTREN 2.0 LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 L dialysate fill volume
Study: 10809242
Drug: 2.5 L
Normalized name: ALCOHOL 1.875 L in 2.5 L TOPICAL LIQUID [EXIHUAN Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 L dialysate fill volume
Study: 10809242
Drug: 3.0 L
Normalized name: The full generic name for the drug abbreviation '3.0 L' is not clear from the information provided. The abbreviation '3.0 L' could refer to various drug formulations or dosages, and without more context, it is not possible to determine the specific full generic name. The best response would be to indicate that the full generic name cannot be determined from the given information.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 L dialysate fill volume
Study: 8752629
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of dexamethasone
Study: 6340970
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg tiaprofenic acid daily for 3 months
Study: 6340970
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg indomethacin daily for 3 months
Study: 29656569
Drug: Small‐quantity lipid‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small‐quantity lipid‐based nutrient supplements (SQ‐LNS)
Study: 18160927
Drug: Point injection
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point injection
Study: 16336289
Drug: Tiotropium therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium therapy alone (Control)
Study: 31194943
Drug: Early clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early clinical assessment of dysphagia before oral intake; therapeutic interventions implemented immediately for diagnosed dysphagia
Study: 28244408
Drug: GemX (gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GemX (gemcitabine chemotherapy at 100 mg/m2 with concurrent radiation therapy at a total dose of 52.5 Gy in 20 fractions)
Study: 28244408
Drug: neoGemX (gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: neoGemX (gemcitabine chemotherapy at 100 mg/m2 with concurrent radiation therapy at a total dose of 52.5 Gy in 20 fractions following NAC)
Study: 26718518
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with clopidogrel (triple-C)
Study: 26718518
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with prasugrel (triple-P)
Study: 26718518
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with clopidogrel (dual-C)
Study: 26718518
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with prasugrel (dual-P)
Study: 26718518
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (both triple-C and triple-P)
Study: 22892368
Drug: Multi-sugar (MS)
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-sugar (MS) test (1 g sucrose, lactulose, sucralose, erythritol, 0.5 g rhamnose in water) after indomethacin
Study: 22892368
Drug: Dual sugar
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual sugar (DS) test (5 g lactulose, 0.5 g rhamnose) after indomethacin
Study: 15471656
Drug: Dexamethasone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (20 mg/day)
Study: 11915694
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Control Group 3, 30 patients)
Study: 7976142
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml 0.5% lidocaine with 2 mg of atracurium
Study: 7976142
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml 0.5% lidocaine
Study: 27783162
Drug: Subcutaneous closed-suction
Normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous closed-suction drainage arm
Study: 27783162
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (no subcutaneous drainage)
Study: 21519837
Drug: CEF adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEF adjuvant chemotherapy
Study: 21519837
Drug: CMF adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF adjuvant chemotherapy
Study: 18370574
Drug: Aripiprazole (5-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (5-30 mg/day)
Study: 16565827
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (7 or 14 mg)
Study: 11090796
Drug: 60-minute determination
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60-minute determination of ST-segment resolution after thrombolytic therapy
Study: 11090796
Drug: 90-minute determination
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90-minute determination of ST-segment resolution after thrombolytic therapy
Study: 1526219
Drug: 3,4-diaminopyridine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3,4-diaminopyridine + anti-cholinesterase medication
Study: 2989052
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g bran daily
Study: 29126173
Drug: Inactivated poliovirus
Normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated poliovirus vaccine (IPV) at all time points (Arm A)
Study: 29126173
Drug: Bivalent oral
Normalized name: Non-US bivalent oral polio vaccine (types 1 and 3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent oral poliovirus vaccine (bOPV) at all time points (Arm B)
Study: 29126173
Drug: Inactivated poliovirus
Normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated poliovirus vaccine (IPV) at final time point (Arm D)
Study: 26983976
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (once-per-day)
Study: 26983976
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical corticosteroids
Study: 24671338
Drug: Dextroamphetamine (sensitising
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine (sensitising dosage pattern)
Study: 22464810
Drug: Golden Delicious
Normalized name: GOLDEN SEAL
DrugBank: Goldenseal (DB16594)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golden Delicious apple juice (300 mL)
Study: 22464810
Drug: Catarina apple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catarina apple juice (300 mL)
Study: 17823908
Drug: Docetaxel/gemcitabine (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel/gemcitabine (docetaxel 30 mg/m(2) + gemcitabine 800 mg/m(2))
Study: 17823908
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel (36 mg/m(2))
Study: 15339495
Drug: Conventional steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional steroid plus kidney-warming and astringent therapy (treatment group)
Study: 15339495
Drug: Conventional steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional steroid treatment (control group)
Study: 11691528
Drug: Dual-chamber pacemaker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-chamber pacemaker implant (paced patients)
Study: 11691528
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (controls)
Study: 2690768
Drug: Danazol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (600 mg/day)
Study: 2801831
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (100 mg/day)
Study: 49745
Drug: Intermittent short
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent short duration intravenous infusions
Study: 31376356
Drug: Maltodextrin-based feed
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin-based feed with lysozyme product (Inovapure) at 20 g/kg
Study: 31376356
Drug: Maltodextrin-based feed
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin-based feed with lysozyme product (Inovapure) at 10 g/kg
Study: 31376356
Drug: Maltodextrin-based feed
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin-based feed with lysozyme product (Inovapure) at 0 g/kg
Study: 26908424
Drug: Soft gel
Normalized name: Norvir Soft Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gel capsules containing MK-7
Study: 26908424
Drug: Soft gel
Normalized name: Norvir Soft Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gel capsules
Study: 23185760
Drug: Ginkgo Biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo Biloba Tablet (GBT), 1 tablet each time, 3 times a day for 12 months
Study: 23185760
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (basic treatment only)
Study: 19829141
Drug: Local intracoronary
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local intracoronary infusion of abciximab through the ClearWayRX System
Study: 19829141
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of abciximab via the guiding catheter
Study: 19829141
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups receive intravenous infusion of abciximab during the 12‐h period following the procedure
Study: 17608573
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser treatment (160 mJ/pulse at 10 Hz)
Study: 17608573
Drug: Ultrasonic scaler
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic scaler treatment
Study: 11261739
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg/die administered at 10.00 PM
Study: 11261739
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg/die administered at 8.00 AM
Study: 11261739
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg/die administered at 4.00 PM
Study: 11261739
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg/die administered at night (10.00 PM)
Study: 1961957
Drug: Propofol induction
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol induction (2.5 mg/kg)
Study: 1961957
Drug: Thiopental induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental induction (4-5 mg/kg)
Study: 20310020
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g mesalamine suppository once daily
Study: 20310020
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g mesalamine suppository thrice daily
Study: 12150347
Drug: 10% triacylglycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% triacylglycerol emulsion (500 ml, 450 Kcal)
Study: 12150347
Drug: 20% triacylglycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% triacylglycerol emulsion (500 ml, 900 Kcal)
Study: 7597305
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with IFN alpha and high-dose IL-2
Study: 7597305
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with dacarbacine (DTIC) followed by IFN-alpha
Study: 7597305
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of DTIC or cisplatinum (CDDP) followed by IFN-alpha/IL-2
Study: 6975997
Drug: Phenprocoumon (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenprocoumon (oral anticoagulant therapy)
Study: 6975997
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no oral anticoagulant therapy)
Study: 31856909
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg every 2 weeks) plus Denosumab (120 mg every 2 weeks, following nivolumab)
Study: 15082280
Drug: Aminophylline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (5 mg/kg intravenously after induction, maintained with 0.5 mg/kg per hour)
Study: 8957982
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate 0.3 mol litre‐1 (antacid)
Study: 8957982
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate dehydrate (100 mg ml‐1) with citric acid monohydrate (66 mg ml‐1) (buffer)
Study: 8957982
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no gastric solution)
Study: 7687142
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight hydroxyethyl starch solution (LMW‐HES) (6% HES; mean molecular weight 200,000 Da, molar substitution 0.5)
Study: 3698726
Drug: Single-dose mezlocillin
Normalized name: mezlocillin
DrugBank: Mezlocillin (DB00948)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose mezlocillin (5 grams preoperative)
Study: 3698726
Drug: Multiple-dose mezlocillin
Normalized name: mezlocillin
DrugBank: Mezlocillin (DB00948)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple-dose mezlocillin (3 doses of 2 grams perioperative)
Study: 30414284
Drug: OIT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OIT with pasteurized egg white (PEW) - daily 3.3 g proteins (AG)
Study: 22882698
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m²) plus cisplatin (75 mg/m²)
Study: 22882698
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m² on days 1 and 8) plus cisplatin (75 mg/m²)
Study: 15260907
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of 5-hydroxytryptophan (5-HTP)
Study: 15260907
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of 5-hydroxytryptophan (5-HTP) in females
Study: 15260907
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of 5-hydroxytryptophan (5-HTP) in males
Study: 11416734
Drug: Structured treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured treatment interruptions (STI) in 12 patients
Study: 8361472
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg per day added to immuno-chemotherapy (Tegaful, Mitomycin, Krestin, OK-432)
Study: 8361472
Drug: Tamoxifen in
Normalized name: Product containing tamoxifen in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen in cases with estrogen receptor
Study: 8361472
Drug: Tamoxifen in
Normalized name: Product containing tamoxifen in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen in cases without estrogen receptor
Study: 21760633
Drug: Treatment preference
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment preference
Study: 8896540
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated varicella vaccine (Oka/SB Bio)
Study: 1803786
Drug: Lanoxin 0.125
Normalized name: Lanoxin 0.125mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanoxin 0.125 mg
Study: 1803786
Drug: Lanoxicaps 0.1
Normalized name: Lanoxicaps 0.1mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanoxicaps 0.1 mg
Study: 1803786
Drug: Lanoxin 0.25
Normalized name: Lanoxin 0.25mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanoxin 0.25 mg
Study: 1803786
Drug: Lanoxicaps 0.2
Normalized name: Lanoxicaps 0.2mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanoxicaps 0.2 mg
Study: 26037245
Drug: Doxazosin (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (titrated to 16 mg/day)
Study: 9612619
Drug: Adjuvant 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant 5-fluorouracil based chemotherapy
Study: 7751115
Drug: Titanium-reinforced membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titanium-reinforced membrane and osseointegrated implants
Study: 2661788
Drug: Metoclopramide 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 0.1 mg/kg four times a day, 1/2 hour before feeding for 1 week
Study: 29931294
Drug: Traditional orthodontic
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional orthodontic treatment (Control)
Study: 25713025
Drug: Regular aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular aspirin use (moderate versus nonregular use)
Study: 27029746
Drug: Ibuprofen use
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen use
Study: 16507028
Drug: Group treatment
Normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group treatment programme for depression
Study: 10945511
Drug: Estradiol matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol matrix transdermal system (0.1 mg/d)
Study: 10945511
Drug: Estradiol matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol matrix transdermal system (0.05 mg/d)